A LinkedIn post from Single Quantum highlights the company’s planned presence at APS March 2026, where its technology will be featured in an invited talk by Dr. Katyayani Seal. The session will focus on a quantum detector system using superconducting nanowire single-photon detectors, or SNSPDs, for hybrid time-domain diffuse optics in biomedical applications.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to the post, the talk will address how diffuse optics techniques such as time-domain near-infrared spectroscopy and time-domain diffuse correlation spectroscopy can monitor blood flow and oxygen saturation non-invasively. The content suggests Single Quantum is positioning its SNSPDs as enabling components for these applications, emphasizing high near-infrared efficiency, temporal resolution, and low dark count rates.
For investors, the focus on biomedical use cases may indicate an effort to diversify revenue opportunities beyond traditional quantum and photonics markets. Visibility at a major physics conference with an invited talk could also support the company’s credibility among academic and industrial researchers, potentially strengthening future collaboration and commercialization prospects in medical imaging and monitoring technologies.